RSV booster shot shows promise for seniors
NCT ID NCT07117487
First seen Feb 02, 2026 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This study tested a new mRNA booster shot (mRNA-1345) in 507 adults aged 60 and older who had already received a licensed RSV vaccine at least a year earlier. The goal was to see if the booster is safe and boosts the immune system's ability to fight RSV. Researchers measured side effects and antibody levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Indago Research & Health Center, Inc.
Hialeah, Florida, 33012, United States
-
Velocity Clinical Research, Austin
Austin, Texas, 78759, United States
-
Velocity Clinical Research, Covington
Covington, Louisiana, 70433, United States
-
Velocity Clinical Research, Denver
Denver, Colorado, 80110, United States
-
Velocity Clinical Research, Hampton
Hampton, Virginia, 23666, United States
-
Velocity Clinical Research, Lincoln
Lincoln, Nebraska, 68510, United States
-
Velocity Clinical Research, Medford
Medford, Oregon, 97504, United States
-
Velocity Clinical Research, Rockville
Rockville, Maryland, 20854, United States
-
Velocity Clinical Research, Savannah
Savannah, Georgia, 31406, United States
-
Velocity Clinical Research, Spokane
Spokane, Washington, 99218, United States
-
Velocity Clinical Research, Valparaiso
Valparaiso, Indiana, 46383, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-1345 (an mRNA-based RSV vaccine booster)
What this could lead to
If successful, this could show that an mRNA booster safely strengthens protection against RSV in older adults who already received a different RSV vaccine.
What could go wrong
This is a completed phase 3 study, but results are not yet published. The booster may not provide significantly better immunity than the original vaccine, and side effects like injection site pain or fever are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.